EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis

Wanyi Sun iD, Yun Wu, Fei Ma, Jinhu Fan, Youlin Qiao iD

Journal of Clinical Medicine · 17.02.2023 · 12 (4) · 1588

DOI: 10.3390/jcm12041588 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.02.2023. Verfasst von Wanyi Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Epidemiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical …. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The optimal treatment regimen for breast cancer patients with gBRCA mutations remains controversial given the availability of numerous options, such as platinum-based agents, polymerase inhibitors (PARPis), and other agents. We included phase II or III RCTs and estimated the HR with 95% CI for OS, PFS, and DFS, in addition to the OR with 95% CI for ORR and pCR. We determined the treatment arm rankings by P-scores. Furthermore, we carried out a subgroup analysis in TNBC and HR-positive patients. We conducted this network meta-analysis using R 4.2.0 and a random-effects model. A total of 22 RCTs were eligible, involving 4253 patients. In the pairwise comparisons, PARPi + Platinum + Chemo was better than PARPi + Chemo for OS (in whole study group and in both subgroups) as well as PFS. The ranking tests demonstrated that PARPi + Platinum + Chemo ranked first in PFS, DFS, and ORR. Platinum + Chemo showed higher OS than PARPi + Chemo. The ranking tests for PFS, DFS, and pCR indicated that, except for the best treatment (PARPi + Platinum + Chemo) containing PARPi, the second and third treatments were platinum monotherapy or platinum-based chemotherapy. In conclusion, PARPi + Platinum + Chemo might be the best regime for gBRCA-mutated BC. Platinum drugs showed more favorable efficacy than PARPi in both combination and monotherapy.

Schlagwörter

Stichwörter der Autor:innen

BRCA-mutated HER2-negative breast cancerefficacyimmunotherapynetwork meta-analysisplatinumpolymerase inhibitors

Autor:innen und Institutionen

  • Department of Cancer Epidemiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100124, China.
  • Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100124, China.
  • Center for Global Health, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100124, China.

ORCID-Profile: Wanyi Sun, Youlin Qiao

Zitieren

APA

Sun, W., Wu, Y., Ma, F., Fan, J., & Qiao, Y. (2023). Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 12(4), 1588. https://doi.org/10.3390/jcm12041588

Vancouver

Sun W, Wu Y, Ma F, Fan J, Qiao Y. Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine. 2023;12(4):1588. doi:10.3390/jcm12041588

BibTeX
@article{Sun2023,
  author = {Sun, Wanyi and Wu, Yun and Ma, Fei and Fan, Jinhu and Qiao, Youlin},
  title = {Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {1588},
  doi = {10.3390/jcm12041588}
}
Kostenlos starten →